Biomarkers predictive of PD1/PD-L1 immunotheraphy in non-small cell lung cancer

被引：4

作者：

Lupo, A. ^{[1
,2
,3
,4
]}

Alifano, M. ^{[2
,5
]}

Wislez, M. ^{[1
,2
,3
,4
,6
]}

Boulle, G. ^{[1
,2
,3
]}

Velut, Y. ^{[1
,2
,3
]}

Biton, J. ^{[7
]}

Cremer, I. ^{[1
,2
,3
]}

Goldwasser, F. ^{[2
,8
]}

Leroy, K. ^{[2
,9
]}

Damotte, D. ^{[1
,2
,3
,4
]}

机构：

[1] INSERM, UMRS 1138, Equipe Canc Immune Control & Escape, Ctr Rech Cordeliers, Paris, France

[2] Univ Paris 05, F-75006 Paris, France

[3] Univ Pierre & Marie Curie Paris, F-75005 Paris, France

[4] Hop Cochin, AP HP, Serv Pathol, F-75014 Paris, France

[5] Hop Cochin, AP HP, Serv Chirurg Thorac, F-75014 Paris, France

[6] Hop Tenon, AP HP, Serv Pneumol, F-75014 Paris, France

[7] Univ Paris 13, Sorbonne Paris Cite, Lab Immunol & Immunopathol Li2P, Inserm UMR 1125,Physiopathol Cibles & Therapies P, F-93000 Bobigny, France

[8] Hop Cochin, AP HP, Serv Oncol Med, F-75014 Paris, France

[9] Hop Cochin, AP HP, Serv Genet & Biol Mol, F-75014 Paris, France

来源：

REVUE DE PNEUMOLOGIE CLINIQUE | 2018年 / 74卷 / 05期

关键词：

Lung cancer; Biomarkers; Immune checkpoint inhibitors; Immunotherapy; PULMONARY SQUAMOUS-CELL; PD-1; BLOCKADE; ANTI-PD-L1; ANTIBODY; CLINICAL-RESPONSE; CTLA-4; OPEN-LABEL; EXPRESSION; IMMUNOHISTOCHEMISTRY; MICROENVIRONMENT; MULTICENTER;

D O I：

10.1016/j.pneumo.2018.09.010

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Immune checkpoint inhibitors (ICI), targeting the PD1/PD-L1 axis has shown their efficacy in lung cancer but only in a restricted population of patients, thus it is mandatory to identify biomarkers predicting the clinical benefit. In this article we will describe and analyzed biomarkers already published, from protein, to RNA and at last DNA markers, discussing each markers feasibility and interest. In the future, combined analysis of several markers will probably be proposed, particularly with the increasing complexity of therapy schema with molecules association. (C) 2018 Elsevier Masson SAS. All rights reserved.

引用

页码：339 / 350

页数：12

共 50 条

[41] Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer [J].

Scheel, Andreas H. ;

Baenfer, Gudrun ;

Baretton, Gustavo ;

Dietel, Manfred ;

Diezko, Rolf ;

Henkel, Thomas ;

Heukamp, Lukas C. ;

Jasani, Bharat ;

Joehrens, Korinna ;

Kirchner, Thomas ;

Lasitschka, Felix ;

Petersen, Iver ;

Reu, Simone ;

Schildhaus, Hans-Ulrich ;

Schirmacher, Peter ;

Schwamborn, Kristina ;

Sommer, Ulrich ;

Stoss, Oliver ;

Tiemann, Markus ;

Warth, Arne ;

Weichert, Wilko ;

Wolf, Juergen ;

Buettner, Reinhard ;

Rueschoff, Josef .

HISTOPATHOLOGY, 2018, 72 (03) :449-459

[42] The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer [J].

Qu, Jingjing ;

Mei, Quanhui ;

Liu, Li ;

Cheng, Tianli ;

Wang, Peng ;

Chen, Lijun ;

Zhou, Jianying .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13

[43] PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges [J].

Meng, Xiangjiao ;

Liu, Yanli ;

Zhang, Jianjun ;

Teng, Feifei ;

Xing, Ligang ;

Yu, Jinming .

CANCER LETTERS, 2017, 405 :29-37

[44] PD-1/PD-L1 inhibitors in treatment-naive, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials [J].

Wankhede, Durgesh ;

Hofman, Paul ;

Grover, Sandeep .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) :2179-2189

[45] Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? [J].

Chae, Young Kwang ;

Pan, Alan ;

Davis, Andrew A. ;

Raparia, Kirtee ;

Mohindra, Nisha A. ;

Matsangou, Maria ;

Giles, Francis J. .

CLINICAL LUNG CANCER, 2016, 17 (05) :350-361

[46] Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy [J].

Meng, Xiangjiao ;

Huang, Zhaoqin ;

Teng, Feifei ;

Xing, Ligang ;

Yu, Jinming .

CANCER TREATMENT REVIEWS, 2015, 41 (10) :868-876

[47] Beyond PD-L1: Assessment of LAG-3 and other predictive biomarkers in non-small cell lung carcinoma [J].

Hung, Yin P. ;

Mino-Kenudson, Mari .

CANCER CYTOPATHOLOGY, 2023, 131 (03) :151-153

[48] PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? [J].

Grigg, Claud ;

Rizvi, Naiyer A. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4

[49] PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer? [J].

Dong, Aoran ;

Zhao, Yiming ;

Li, Zhihua ;

Hu, Hai .

JOURNAL OF GENE MEDICINE, 2021, 23 (02)

[50] THE CHALLENGES OF USING PD-L1 AS A PREDICTIVE BIOMARKER AND THE THERAPEUTIC APPROACH IN NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY [J].

Patcas, Adela ;

Mogosan, Cristina ;

Alexescu, Teodora Gabriela ;

Bordea, Ioana Roxana ;

Buzoianu, Anca Dana ;

Todea, Doina Adina .

FARMACIA, 2020, 68 (03) :390-395

← 1 2 3 4 5 →